The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic Function
Open accessAbstract
The p53 tumor suppressor protein is a sequence-specific transcriptional activator, a function which contributes to cell cycle arrest and apoptosis induced by p53 in appropriate cell types. Analysis of a series of p53 point mutants has revealed the potential for selective loss of the ability to transactivate some, but not all, cellular p53-responsive promoters. p53 175P and p53 181L are tumor-derived p53 point mutants which were previously characterized as transcriptionally active. Both mutants retained the ability to activate expression of the cyclin-dependent kinase inhibitor p2lcip1/waf1, and this activity correlated with the ability to induce a G1 cell cycle arrest. However, an extension of this survey to include other p53 targets showed that p53 175P was defective in the activation of p53-responsive sequences derived from the bax promoter and the insulin-like growth factor-binding protein 3 gene (IGF-BP3) promoter, while p53 181L showed loss of the ability to activate a promoter containing IGF-BP3 box B sequences. Failure to activate transcription was also reflected in the reduced ability of the mutants to bind the p53-responsive DNA sequences present in these promoters. These specific defects in transcriptional activation correlated with the impaired apoptotic function displayed by these mutants, and the results suggest that activation of cell cycle arrest genes by p53 can be separated from activation of genes with a role in mediating the p53 apoptotic response. The cellular response to p53 activation may therefore depend, at least in part, on which group of p53-responsive genes become transcriptionally activated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Variant p.R175H is fully denatured and displays a total loss of function (LOF), including impaired growth arrest and apoptosis [39, 43].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death
Knudson, C. M., Tung, K. S. K., Tourtellotte, W. G., Brown, G. A. J., & Korsmeyer, S. J. (1995) · Science · doi:10.1126/science.270.5233.96 · Cited by 1,493
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · cited 2×
“Analysis of cells from p21 -deficient mice demonstrated a partial loss of the normal p53-induced cell cycle arrest, suggesting that p21 is a major, but not the sole, mediator of this response (6, 17).”
BackgroundGerm-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Induction of the growth inhibitor IGF-binding protein 3 by p53
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., & Kley, N. (1995) · Nature · doi:10.1038/377646a0 · Cited by 869
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes
Caelles, C., Helmberg, A., & Karin, M. (1994) · Nature · doi:10.1038/370220a0 · Cited by 843
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines.
Harrington, E. A., Bennett, M. R., Fanidi, A., & Evan, G. I. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06630.x · Cited by 742
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 653
Structural aspects of the p53 protein in relation to gene evolution.
Soussi, T., de Fromentel, C. C., & May, P. (1990) · PubMed · Cited by 603
Induction of apoptosis in HeLa cells by trans-activation-deficient p53.
Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., & Oren, M. (1995) · Genes & Development · doi:10.1101/gad.9.17.2170 · Cited by 545
Self-citationWagner, A. J., Kokontis, J. M., & Hay, N. (1994) · Genes & Development · doi:10.1101/gad.8.23.2817 · Cited by 539
An immunochemical analysis of the human nuclear phosphoprotein p53
Vojtěšek, B., Bártek, J., Midgley, C. A., & Lane, D. P. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90122-a · Cited by 531
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Sequence-specific transcriptional activation is essential for growth suppression by p53.
Pietenpol, J. A., Tokino, T., Thiagalingam, S., el-Deiry, W. S., Kinzler, K. W., & Vogelstein, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.1998 · Cited by 406
Growth factor modulation of p53-mediated growth arrest versus apoptosis.
Canman, C. E., Gilmer, T. M., Coutts, S. B., & Kastan, M. B. (1995) · Genes & Development · doi:10.1101/gad.9.5.600 · Cited by 365
Slebos, R. J., Lee, M. H., Plunkett, B. S., Kessis, T. D., Williams, B. O., Jacks, T., Hedrick, L., Kastan, M. B., & Cho, K. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5320 · Cited by 344
An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription.
Lam, E. W., & Watson, R. J. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05932.x · Cited by 342
Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases
Wang, Y., & Prives, C. (1995) · Nature · doi:10.1038/376088a0 · Cited by 336
p53 in signaling checkpoint arrest or apoptosis
Bates, S., & Vousden, K. H. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90004-0 · Cited by 331
Self-citationSpecific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., & Vousden, K. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00418.x · Cited by 301
Self-citationA Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis
Friedlander, P., Haupt, Y., Prives, C., & Oren, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4961 · Cited by 278
Transcriptional activation by p53 correlates with suppression of growth but not transformation
CROOK, T. (1994) · Cell · doi:10.1016/0092-8674(94)90071-x · Cited by 233
Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
Haupt, Y., Barak, Y., & Oren, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00504.x · Cited by 228
Essential role for p53-mediated transcription in E1A-induced apoptosis.
Sabbatini, P., Lin, J., Levine, A. J., & White, E. (1995) · Genes & Development · doi:10.1101/gad.9.17.2184 · Cited by 215
Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents.
Collins, M. K., Marvel, J., Malde, P., & Lopez-Rivas, A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.4.1043 · Cited by 214
Demers, G. W., Foster, S. A., Halbert, C. L., & Galloway, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4382 · Cited by 172
Gottlieb, E., Haffner, R., von Rüden, T., Wagner, E. F., & Oren, M. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06390.x · Cited by 163
Crook, T., & Vousden, K. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05487.x · Cited by 148
Self-citationp53-mediated apoptosis in HeLa cells can be overcome by excess pRB.
Haupt, Y., Rowan, S., & Oren, M. (1995) · PubMed · Cited by 133
Allday, M. J., Inman, G. J., Crawford, D., & Farrell, P. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00182.x · Cited by 125
Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Chen, J. Y., Funk, W. D., Wright, W. E., Shay, J. W., & Minna, J. D. (1993) · PubMed · Cited by 114
Es, H., Picksley, S. M., & Kh, V. (1994) · PubMed · Cited by 88
Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis.
Katayose, D., Wersto, R. P., Cowan, K. H., & Seth, P. K. (1995) · PubMed · Cited by 84
Fredersdorf, S., Milne, A. W., Hall, P. A., & Lü, X. (1996) · Europe PMC (PubMed Central) · Cited by 74
Yonish-Rouach, E., Deguin, V., Zaitchouk, T., Breugnot, C., Mishal, Z., Jenkins, J. R., & May, E. (1995) · PubMed · Cited by 67
Regulation of p53-Mediated Apoptosis and Cell Cycle Arrest by Steel Factor
Abrahamson, J., Lee, J. M., & Bernstein, A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6953 · Cited by 64
Modulation of transcriptional regulatory properties of p53 by HPV E6.
Crook, T., Fisher, C., Masterson, P. J., & Kh, V. (1994) · PubMed · Cited by 60
Discrimination of DNA Binding Sites by Mutant p53 Proteins
Thukral, S. K., Lu, Y., Blain, G. C., Harvey, T. S., & Jacobsen, V. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.5196 · Cited by 48
Kobayashi, T., Consoli, U., Andreeff, M., et al. (1995) · PubMed · Cited by 37
Oncogenes and cell proliferation
Marshall, C., & Wyllie, A. H. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90002-7 · Cited by 30
(1995) · PubMed
Cited by
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Self-citationTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Self-citationMuller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Self-citationUnravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
Metadata
- Authors
- Ludwig, R. L., Bates, S., & Vousden, K. H.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1996-09-01
- Volume
- 16
- Issue
- 9
- Pages
- 4952-4960
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W1863595524
- Cited by
- 275
- References
- 56
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.